GSK’s blood cancer drug fails main goal of superiority trial
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
British drugmaker GSK Plc said on Monday its blood cancer drug Blenrep failed the main goal of a late-stage study designed to show that the treatment was better than the standard of care on the market.
:max_bytes(150000):strip_icc():format(jpeg)/socialsecurity-whentoapply-794e7d2e1615450a9c7530288e2f5dad.jpg "Unlocking Benefits: The Best Time to Apply for Social Security")
:max_bytes(150000):strip_icc():format(jpeg)/creditscorecheck-c254d4f39aae46919b846f0f391011c6.jpg "Watch Out for These Top Internet Scams")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-685011611-3857c64421274483b5cc2ee96db5b57e.jpg "How to Choose a Credit Repair Company")
:max_bytes(150000):strip_icc():format(jpeg)/globaltrade-8e91fb7b1b8047988ef6b7acb0280bf5.png "International (Global) Trade: Definition, Benefits, and Criticisms")
:max_bytes(150000):strip_icc():format(jpeg)/Mediation-56a260535f9b58b7d0c975bb.jpg "How Divorce Impacts Your Credit Score")